¼¼°èÀÇ ½ÉÀåÇ÷°ü¿ë µðÁöÅÐ Çコ ½ÃÀå
Digital Health for Cardiovascular
»óǰÄÚµå : 1786432
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 282 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,204,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,612,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ ½ÉÀåÇ÷°ü¿ë µðÁöÅÐ Çコ ½ÃÀåÀº 2030³â±îÁö 1,193¾ï ´Þ·¯¿¡ µµ´Þ

2024³â¿¡ 419¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ¼¼°èÀÇ ½ÉÀåÇ÷°ü¿ë µðÁöÅÐ Çコ ½ÃÀåÀº 2024-2030³â¿¡ CAGR 19.1%·Î ¼ºÀåÇϸç, 2030³â¿¡´Â 1,193¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ ¸®Æ÷Æ®¿¡¼­ ºÐ¼®ÇÑ ºÎ¹®ÀÇ ÇϳªÀÎ ¼ÒÇÁÆ®¿þ¾î ÄÄÆ÷³ÍÆ®´Â CAGR 17.0%¸¦ ±â·ÏÇϸç, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 624¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. Çϵå¿þ¾î ÄÄÆ÷³ÍÆ® ºÐ¾ßÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ Áß CAGR 22.1%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 114¾ï ´Þ·¯, Áß±¹Àº CAGR 25.5%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ½ÉÀåÇ÷°ü¿ë µðÁöÅÐ Çコ ½ÃÀåÀº 2024³â¿¡ 114¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 274¾ï ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 25.5%ÀÔ´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, °¢°¢ ºÐ¼® ±â°£ Áß 15.4%¿Í 16.9%ÀÇ CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR ¾à 15.9%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°è ½ÉÇ÷°ü µðÁöÅÐ Çコ ½ÃÀå - ÁÖ¿ä µ¿Çâ ¹× ÃËÁø¿äÀÎ Á¤¸®

AI¿Í ¿ø°Ý ¸ð´ÏÅ͸µÀÌ ½ÉÇ÷°ü ÁúȯÀÇ ºÎ´ãÀ» ÁÙÀÏ ¼ö Àִ°¡?

½ÉÇ÷°ü Ä¡·á¿¡¼­ µðÁöÅÐ Çコ ¼Ö·ç¼ÇÀÇ ÅëÇÕÀº ÀΰøÁö´É(AI), ¿ø°Ý ȯÀÚ ¸ð´ÏÅ͸µ(RPM), ¿þ¾î·¯ºí ±â¼úÀ» Ȱ¿ëÇÏ¿© ½ÉÇ÷°ü °Ç°­ »óŸ¦ ½Ç½Ã°£À¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ½ÉÀå °ü·Ã ÁúȯÀ» °ü¸®ÇÏ´Â ¹æ¹ýÀ» À籸¼ºÇϰí ÀÖ½À´Ï´Ù. ½ÉÇ÷°ü Áúȯ(CVD)Àº ¿©ÀüÈ÷ Àü ¼¼°è »ç¸Á·üÀÇ ÁÖ¿ä ¿øÀÎÀ¸·Î Áö¼ÓÀûÀÎ ¸ð´ÏÅ͸µ°ú Á¶±â °³ÀÔ Àü·«ÀÌ ÇÊ¿äÇÕ´Ï´Ù. AI ±â¹Ý ¾Ë°í¸®ÁòÀº ÇöÀç ½ÉÀüµµ(ECG)¸¦ ºÐ¼®ÇÏ¿© ºÎÁ¤¸ÆÀ» °¨ÁöÇϰí ÀáÀçÀûÀÎ ½ÉÀåÁúȯÀ» ¹Ì¸® ¿¹ÃøÇÒ ¼ö ÀÖ½À´Ï´Ù. ½º¸¶Æ®¿öÄ¡, Ä¿³ØÆ¼µå ECG ÆÐÄ¡¿Í °°Àº ¿ø°Ý ¸ð´ÏÅ͸µ ¼Ö·ç¼ÇÀ» ÅëÇØ ÀÇ»ç´Â ȯÀÚ°¡ º´¿øÀ» ÀÚÁÖ ¹æ¹®ÇÏÁö ¾Ê°íµµ ½É¹Ú¼ö º¯È­, Ç÷¾Ð, ºÎÁ¤¸ÆÀ» ÃßÀûÇÒ ¼ö ÀÖ½À´Ï´Ù. AI ±â¹ÝÀÇ °¡»ó ºñ¼­°¡ µîÀåÇϸ鼭 °³ÀÎ ¸ÂÃãÇü Ãßõ, º¹¾à ¾Ë¸², »ýȰ½À°ü °³¼± µîÀ» Á¦°øÇÔÀ¸·Î½á ȯÀÚ Âü¿©¸¦ ´õ¿í Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù. µðÁöÅÐ ½ÉÇ÷°ü°è ¼Ö·ç¼ÇÀº Á¶±â ¹ß°ß°ú Áúº´ °ü¸®¸¦ °­È­ÇÏ´Â ¹Ý¸é, ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ, µ¥ÀÌÅÍ ÇÁ¶óÀ̹ö½Ã ¹®Á¦, »óȯ Á¤Ã¥ µîÀÇ ¹®Á¦´Â ¿©ÀüÈ÷ º¸±ÞÀÇ À庮À¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ±×·¯³ª AI¿Í ¿ø°Ý ¸ð´ÏÅ͸µ ±â¼úÀÌ Áö¼ÓÀûÀ¸·Î ¹ßÀüÇÔ¿¡ µû¶ó º¸´Ù ´Éµ¿ÀûÀ̰í, µ¥ÀÌÅÍ Áß½ÉÀûÀ̸ç, Á¢±Ù¼ºÀÌ ¿ëÀÌÇØÁü¿¡ µû¶ó ½ÉÇ÷°ü Ä¡·á¸¦ º¯È­½Ãų Áغñ°¡ µÇ¾î ÀÖ½À´Ï´Ù.

µðÁöÅÐ Ä¡·á(DTx)´Â ¾î¶»°Ô ½ÉÇ÷°ü °á°ú¸¦ °³¼±ÇÒ ¼ö Àִ°¡?

µðÁöÅÐ Ä¡·á(DTx)´Â ±âÁ¸ Ä¡·á¹ýÀ» º¸¿ÏÇÏ´Â Áõ°Å ±â¹ÝÀÇ ¼ÒÇÁÆ®¿þ¾î ±â¹Ý ÁßÀ縦 Á¦°øÇÔÀ¸·Î½á ½ÉÇ÷°ü Áúȯ °ü¸®ÀÇ °­·ÂÇÑ Åø·Î ºÎ»óÇϰí ÀÖ½À´Ï´Ù. ÀϹÝÀûÀÎ À£´Ï½º ¾Û°ú ´Þ¸® DTx ¼Ö·ç¼ÇÀº ÀÓ»óÀûÀ¸·Î °ËÁõµÇ¾î °íÇ÷¾Ð, °íÄÝ·¹½ºÅ×·Ñ, ºñ¸¸°ú °°Àº ƯÁ¤ ½ÉÇ÷°ü À§Çè ¿äÀÎÀ» Ÿ°ÙÀ¸·Î ¼³°èµÇ¾ú½À´Ï´Ù. ¿À¸¶´Ù Çコ(Omada Health)³ª ¸®ºÀ°í(Livongo)¿Í °°Àº ±â¾÷Àº AI¸¦ Ȱ¿ëÇÑ µðÁöÅÐ ÄÚĪ ÇÁ·Î±×·¥À» °³¹ßÇÏ¿© ȯÀÚ°¡ Çൿ¼öÁ¤ Àü·«À» ÅëÇØ »ýȰ½À°ü °ü·Ã À§Çè¿ä¼Ò¸¦ °ü¸®ÇÒ ¼ö ÀÖµµ·Ï µ½°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ Áö¼ÓÀûÀÎ ¸ð´ÏÅ͸µ Àåºñ¿Í ÅëÇÕµÈ µðÁöÅÐ Ä¡·áÁ¦´Â ½Ç½Ã°£ °æ°í ¹× ÁßÀç ±ÇÀå »çÇ×À» Á¦°øÇÏ¿© ±Þ¼º ½ÉÀå »ç°ÇÀÇ À§ÇèÀ» ÁÙÀÔ´Ï´Ù. °¡Ä¡ ±â¹Ý ÀÇ·á ¸ðµ¨·ÎÀÇ ÀüȯÀº º¸Çè ÇÁ·Î¹ÙÀÌ´õ°¡ µðÁöÅÐ Ä¡·áÁ¦¸¦ º¸ÀåÇÏ´Â ¿øµ¿·ÂÀÌ µÇ°í ÀÖÀ¸¸ç, ÀÌ·¯ÇÑ ¼Ö·ç¼ÇÀÌ È¯Àڵ鿡°Ô ´õ ½±°Ô Á¢±ÙÇÒ ¼ö ÀÖµµ·Ï µ½°í ÀÖ½À´Ï´Ù. ±×·¯³ª ±ÔÁ¦»óÀÇ ¹®Á¦, ÀÇ»çµéÀÇ µµÀÔ ¸Á¼³ÀÓ, Àå±âÀûÀÎ ÀÓ»ó °ËÁõÀÇ Çʿ伺 µîÀÌ ½ÉÇ÷°ü°è ÀÇ·á ºÐ¾ß¿¡¼­ DTx ¼Ö·ç¼ÇÀÇ È®»ê¿¡ ¿©ÀüÈ÷ °É¸²µ¹·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. µðÁöÅÐ Ä¡·áÁ¦´Â ¿¬±¸¸¦ ÅëÇØ ±× È¿°ú°¡ °è¼Ó ÀÔÁõµÊ¿¡ µû¶ó ½ÉÇ÷°ü Áúȯ ¿¹¹æ ¹× °ü¸®ÀÇ ÇÙ½É ¿ä¼Ò°¡ µÉ °ÍÀ¸·Î ±â´ëµÇ°í ÀÖ½À´Ï´Ù.

°³ÀÎ ¸ÂÃãÇü ½ÉÇ÷°ü Ä¡·á¿¡¼­ AI¿Í ºòµ¥ÀÌÅÍÀÇ ¿ªÇÒÀº?

AI¿Í ºòµ¥ÀÌÅÍ ºÐ¼®Àº °³ÀÎÀÇ À¯ÀüÀû, ´ë»çÀû, »ýȰ½À°üÀû ¿äÀο¡ ±â¹ÝÇÑ Á¤¹ÐÀÇ·á Á¢±ÙÀ» °¡´ÉÇÏ°Ô ÇÏ´Â ½ÉÇ÷°ü Ä¡·á °èȹÀÇ °³ÀÎÈ­¿¡¼­ Á¡Á¡ ´õ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ¸Ó½Å·¯´× ¸ðµ¨Àº ÀüÀÚÀǹ«±â·Ï(EHR), À¯ÀüÀÚ ¸¶Ä¿, ȯÀÚ º¸°í µ¥ÀÌÅÍ µî ¹æ´ëÇÑ µ¥ÀÌÅͼ¼Æ®¸¦ ºÐ¼®ÇÏ¿© ½ÉÇ÷°ü ȯÀÚÀÇ °³ÀÎ ¸ÂÃãÇü Ä¡·á °æ·Î¸¦ ½Äº°ÇÏ´Â µ¥ »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. AI ±â¹Ý À§Çè ¿¹Ãø ¸ðµ¨Àº ½ÉÀ庴 ¹ßº´ °¡´É¼º¿¡ µû¶ó ȯÀÚ¸¦ °èÃþÈ­ÇÏ¿© Á¶±â °³ÀÔ°ú Ç¥ÀûÈ­µÈ ¿¹¹æ Á¶Ä¡¸¦ °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù. ¶ÇÇÑ AI ±â¹Ý 꺿°ú ¿ø°ÝÀÇ·á Ç÷§ÆûÀº ¸ÂÃãÇü ÃßõÀ» Á¦°øÇϰí, ½ÉÇ÷°ü °Ç°­ °ü·Ã ¹®ÀÇ¿¡ ½Ç½Ã°£À¸·Î ´äº¯ÇÔÀ¸·Î½á ȯÀÚ Âü¿©¸¦ Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù. ¾öû³­ ÀáÀç·Â¿¡µµ ºÒ±¸ÇÏ°í ½ÉÇ÷°ü ÀÇ·á ºÐ¾ß¿¡¼­ AIÀÇ ´É·ÂÀ» ÃÖ´ëÇÑ È°¿ëÇϱâ À§Çؼ­´Â AI ¸ðµ¨ÀÇ ÆíÇ⼺, µ¥ÀÌÅÍ »óÈ£¿î¿ë¼º ¹®Á¦, ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ Çʿ伺 µîÀÇ ¹®Á¦¸¦ ÇØ°áÇØ¾ß ÇÕ´Ï´Ù. ±×·¯³ª ºòµ¥ÀÌÅͰ¡ Á¤¹ÐÀÇ·áÀÇ Á¢±Ù¹ýÀ» °è¼Ó Á¤±³È­ÇÔ¿¡ µû¶ó AI´Â ½ÉÇ÷°ü Ä¡·á °á°ú¸¦ ÃÖÀûÈ­ÇÏ´Â µ¥ ÇʼöÀûÀÎ ¿ªÇÒÀ» ÇÒ °ÍÀ¸·Î ±â´ëµÇ°í ÀÖ½À´Ï´Ù.

½ÉÇ÷°ü µðÁöÅÐ Çコ ½ÃÀåÀÇ ¼ºÀå ¿øµ¿·ÂÀº?

½ÉÇ÷°ü µðÁöÅÐ Çコ ½ÃÀåÀÇ ¼ºÀåÀº ½ÉÀ庴 À¯º´·ü Áõ°¡, ¿þ¾î·¯ºí Çコ ±â¼ú äÅà Áõ°¡, AI ±â¹Ý Áø´ÜÀÇ ¹ßÀü µî ¿©·¯ °¡Áö ¿äÀο¡ ÀÇÇØ ÀÌ·ç¾îÁö°í ÀÖ½À´Ï´Ù. Àü ¼¼°è¿¡¼­ ¿ø°ÝÀÇ·á ¼­ºñ½º·ÎÀÇ ÀüȯÀ¸·Î ¿ø°Ý ȯÀÚ ¸ð´ÏÅ͸µ ¹× ÀçÅà ½ÉÀå °ü¸® ¼ö¿ä°¡ ±ÞÁõÇϰí ÀÖ½À´Ï´Ù. ±ÔÁ¦ ´ç±¹µµ µðÁöÅÐ °Ç°­ °³ÀÔÀÇ Á߿伺À» ÀνÄÇϰí ÀÖÀ¸¸ç, µðÁöÅÐ ½ÉÇ÷°ü°è ¼Ö·ç¼Ç¿¡ ´ëÇÑ ½ÂÀΰú »óȯ Áö¿øÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ºí·ÏüÀΰú »çÀ̹ö º¸¾È Á¶Ä¡ÀÇ ÅëÇÕÀº ȯÀÚ µ¥ÀÌÅÍÀÇ º¸¾ÈÀ» °­È­ÇÏ°í µðÁöÅÐ Çコ Ç÷§Æû¿¡ ´ëÇÑ ½Å·Ú¸¦ ³ôÀ̰í ÀÖ½À´Ï´Ù. ¶ÇÇÑ Á¤¹ÐÀÇ·á¿Í °³ÀÎ ¸ÂÃãÇü Ä¡·á Á¢±Ù¹ýÀÇ ºÎ»óÀ¸·Î ÀÎÇØ ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õµéÀº ½ÉÇ÷°ü Ä¡·á¿¡¼­ AI¸¦ Ȱ¿ëÇÑ ¿¹Ãø ºÐ¼®À¸·Î ³ª¾Æ°¡°í ÀÖ½À´Ï´Ù. µðÁöÅÐ Çコ ½ºÅ¸Æ®¾÷¿¡ ´ëÇÑ Áö¼ÓÀûÀÎ ÅõÀÚ¿Í ÇÏÀÌÅ×Å© ±â¾÷, ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õ, º¸Çè»ç °£ÀÇ Àü·«Àû Á¦ÈÞ¸¦ ÅëÇØ µðÁöÅÐ ½ÉÇ÷°ü °Ç°­ ½ÃÀåÀº Å©°Ô ¼ºÀåÇÏ°í ½ÉÀ庴 °ü¸®ÀÇ ¹Ì·¡¸¦ À籸¼ºÇÒ °ÍÀÔ´Ï´Ù.

ºÎ¹®

ÄÄÆ÷³ÍÆ®(¼ÒÇÁÆ®¿þ¾î ÄÄÆ÷³ÍÆ®, Çϵå¿þ¾î ÄÄÆ÷³ÍÆ®, ¼­ºñ½º ÄÄÆ÷³ÍÆ®); ÃÖÁ¾ ¿ëµµ(ȯÀÚ, ÇÁ·Î¹ÙÀÌ´õ, ÁöºÒÀÚ, ±âŸ)

Á¶»ç ´ë»ó ±â¾÷ÀÇ ¿¹

AI ÅëÇÕ

Global Industry Analysts´Â À¯È¿ÇÑ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI Åø¿¡ ÀÇÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ º¯ÇõÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â ÀϹÝÀûÀÎ LLM³ª ¾÷°èº° SLM Äõ¸®¿¡ µû¸£´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ´ë·® ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÔ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå °³¿ä

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Digital Health for Cardiovascular Market to Reach US$119.3 Billion by 2030

The global market for Digital Health for Cardiovascular estimated at US$41.9 Billion in the year 2024, is expected to reach US$119.3 Billion by 2030, growing at a CAGR of 19.1% over the analysis period 2024-2030. Software Component, one of the segments analyzed in the report, is expected to record a 17.0% CAGR and reach US$62.4 Billion by the end of the analysis period. Growth in the Hardware Component segment is estimated at 22.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$11.4 Billion While China is Forecast to Grow at 25.5% CAGR

The Digital Health for Cardiovascular market in the U.S. is estimated at US$11.4 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$27.4 Billion by the year 2030 trailing a CAGR of 25.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 15.4% and 16.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 15.9% CAGR.

Global Digital Health for Cardiovascular Market - Key Trends & Drivers Summarized

Can AI and Remote Monitoring Reduce Cardiovascular Disease Burden?

The integration of digital health solutions in cardiovascular care is reshaping how heart-related diseases are managed, leveraging artificial intelligence (AI), remote patient monitoring (RPM), and wearable technologies to provide real-time insights into cardiovascular health. Cardiovascular diseases (CVDs) remain the leading cause of mortality worldwide, necessitating continuous monitoring and early intervention strategies. AI-driven algorithms are now capable of analyzing electrocardiograms (ECGs), detecting arrhythmias, and predicting potential cardiac events before they occur. Remote monitoring solutions, such as smartwatches and connected ECG patches, allow physicians to track heart rate variability, blood pressure, and irregular heart rhythms without requiring patients to visit hospitals frequently. The rise of AI-powered virtual health assistants is further improving patient engagement by offering personalized recommendations, medication reminders, and lifestyle modifications. While digital cardiovascular solutions enhance early detection and disease management, challenges such as regulatory approval, data privacy concerns, and reimbursement policies remain barriers to widespread adoption. However, as AI and remote monitoring technologies continue to improve, they are poised to transform cardiovascular care by making it more proactive, data-driven, and accessible.

How Are Digital Therapeutics (DTx) Improving Cardiovascular Outcomes?

Digital therapeutics (DTx) are emerging as a powerful tool in cardiovascular disease management, offering evidence-based, software-driven interventions to complement traditional treatments. Unlike general wellness apps, DTx solutions are clinically validated and designed to target specific cardiovascular risk factors such as hypertension, high cholesterol, and obesity. Companies like Omada Health and Livongo are developing AI-powered digital coaching programs that help patients manage lifestyle-related risk factors through behavior modification strategies. Furthermore, digital therapeutics integrated with continuous monitoring devices provide real-time alerts and intervention recommendations, reducing the risk of acute cardiac events. The shift toward value-based healthcare models is also driving insurance providers to cover digital therapeutics, making these solutions more accessible to patients. However, regulatory challenges, physician adoption hesitancy, and the need for long-term clinical validation remain obstacles to scaling DTx solutions in cardiovascular health. As research continues to demonstrate their effectiveness, digital therapeutics are expected to become a core component of cardiovascular disease prevention and management.

What Role Do AI and Big Data Play in Personalized Cardiovascular Care?

AI and big data analytics are playing an increasingly critical role in personalizing cardiovascular treatment plans, allowing for precision medicine approaches based on an individual's genetic, metabolic, and lifestyle factors. Machine learning models are being used to analyze vast datasets, including electronic health records (EHRs), genetic markers, and patient-reported data, to identify personalized treatment pathways for cardiovascular patients. AI-driven risk prediction models can stratify patients based on their likelihood of developing heart disease, enabling early intervention and targeted preventive measures. Additionally, AI-powered chatbots and telehealth platforms are improving patient engagement by providing tailored recommendations and answering cardiovascular health queries in real time. Despite the immense potential, challenges such as bias in AI models, data interoperability issues, and the need for regulatory approvals must be addressed to unlock the full capabilities of AI in cardiovascular healthcare. However, as big data continues to refine precision medicine approaches, AI is expected to play an indispensable role in optimizing cardiovascular treatment outcomes.

What Is Driving the Growth of the Digital Health for Cardiovascular Market?

The growth in the digital health for cardiovascular market is driven by several factors, including the increasing prevalence of heart diseases, rising adoption of wearable health technologies, and advancements in AI-driven diagnostics. The demand for remote patient monitoring and home-based cardiac care is surging due to the global shift toward telehealth services. Regulatory bodies are also recognizing the importance of digital health interventions, leading to increased approvals and reimbursement support for digital cardiovascular solutions. The integration of blockchain and cybersecurity measures is enhancing patient data security, increasing trust in digital health platforms. Additionally, the rise of precision medicine and personalized treatment approaches is pushing healthcare providers toward AI-powered predictive analytics in cardiovascular care. With continued investment in digital health startups and strategic partnerships among tech companies, healthcare providers, and insurers, the digital cardiovascular health market is set to experience significant growth, reshaping the future of heart disease management.

SCOPE OF STUDY:

The report analyzes the Digital Health for Cardiovascular market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Component (Software Component, Hardware Component, Service Component); End-Use (Patients End-Use, Providers End-Use, Payers End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â